Condition-Specific Health
Danone Launches Fermented Foods Toolkit for Clinicians and Chefs
Developed with the Culinary Institute of America and peer-reviewed by Stanford Medicine's Nutrition Studies Research Gr…
Condition-Specific Health 113 stories
Condition-Specific Health
Thryvia Postbiotic Reports 89% Digestive Improvement in Consumer Study
Superbrewed Food pairs the Thryvia consumer study data with a new CEO hire and a Trailblazer Award win, signaling a pus…
Condition-Specific Health
Revita Pivotal Data Advance FDA De Novo Push for Post-GLP-1 Maintenance
Fractyl Health is sharpening its regulatory strategy around Revita after positive pivotal trial results, targeting an F…
Condition-Specific Health
10X Health Debuts Saliva-Based Metabolism Genetic Test
10X Health's new saliva-based test analyzes metabolism-linked genetic markers to help consumers and practitioners build…
Condition-Specific Health
Lifeway Frozen Kefir Returns to Foodservice Soft-Serve
Lifeway Foods is partnering with frozen yogurt shops nationwide to offer soft serve made from live-culture kefir rather…
Condition-Specific Health
KA-EX Names Sports Nutrition Veteran CEO for US Push
KA-EX's patented VICAP dual-chamber technology and dual-format lineup anchor a US retail strategy now spanning GNC, Ear…
Condition-Specific Health
Oral GLP-1 Candidate RV-8451 Targets Muscle Preservation in Obesity
Rivus Pharmaceuticals is bringing preclinical non-human primate obesity data for its oral GLP-1 candidate RV-8451 to Ob…
Condition-Specific Health
Microbiotica Raises $48M to Push Microbiome Drugs Into Phase 2
Microbiotica's Series C financing signals growing investor confidence in orally dosed, precision microbiome therapeutic…
Condition-Specific Health
SER-428 Live Biotherapeutic Targets ICU Bloodstream Infections
Seres Therapeutics is presenting preclinical data for SER-428, a novel oral liquid live biotherapeutic formulated for c…
Condition-Specific Health
Oral GLP-1 Agonist BMF-650 Shows Weight Loss in Phase 1 Trial
Biomea Fusion reports Phase 1 data for BMF-650, an investigational oral GLP-1 receptor agonist showing sustained weight…
Condition-Specific Health
VIVUS Cuts QSYMIA Cash Price to $75 for 30-Day Supply
VIVUS's price reduction positions QSYMIA among the most accessible branded prescription weight-management therapies in …
Condition-Specific Health
IBIO-610 Cuts Lean-Mass Loss to 6% in GLP-1 Combo NHP Study
iBio's IBIO-610 Activin E antibody demonstrated striking muscle-preservation data in obese non-human primates alongside…